The General Hospital Corporation

Harvard College

Children's Medical Center Corporation

Other

Massachusetts Institute of Technology

Genentech, Inc.

Dana-farber-cancer Institute Inc.

Beth Israel Deaconess Medical Center, Inc.

The Brigham and Women's Hospital, Inc.

The Broad Institute, Inc.

Bayer Pharma Aktiengesellschaft

Genetech, Inc.

Beth Israel Medical Center

Cytomatrix, LLC

New England Deaconess Hosp.

David T Scadden

Mark C Poznansky

Henry M Kronenberg

Laura Maria Calvi

Gregor Adams

Derrick J Rossi

Rahul Palchaudhuri

Agnieszka D Czechowicz

Tao Cheng

Paul J Godowski

Melanie Rose Mark

Michael Rosenzweig

Edward M Brown

Todd R Golub

Benjamin L Ebert

David B Sykes

Andrew David Luster

Mark J Pykett

Jun Lu

Shangqin Guo

Lev Silberstein

Peter Kharchenko

Ivona T Olszak

Kevin P Baker

David J Mooney

Timothy A Lewis

Detlef Stöckigt

Andreas Janzer

Will F Baron

Jonathan Hoggatt

Hui Yu

Angelo S Mao

Ting-Yu Shih

Michael K Mansour

Jonas Larsson

Youzhong Yuan

Hongmei Shen

Andrew T Luster

R Paul Johnson

Andrew Freedman

Borja Saez

Nisarg J Shah

Catherine Rhee

Francesca Ferraro

Hanna Meyer

Angelo Mao

Gregor B Adams

Henry Kornenberg

Described herein are compositions comprising subsets of monocyte having distinct functional properties and methods for using the same to treat infectious disease.

Monocyte compositions and methods for the treatment of infectious disease

Disclosed herein are non-myeloablative antibody-toxin conjugates and compositions that target cell surface markers, such as the CD34, CD45 or CD117 receptors, and related methods of their use to effectively conditioning a subject's tissues (e.g., bone marrow tissue) prior to engraftment or transplant. The compositions and methods disclosed herein may be used to condition a subject's tissues in advance of, for example, hematopoietic stem cell transplant and advantageously such compositions and methods do not cause the toxicities that are commonly associated with traditional conditioning methods.

Compositions and methods for non-myeloablative conditioning

Disclosed are compositions and related methods of recapitulating bone marrow stroma using scaffold materials (e.g., a porous alginate hydrogel scaffold) containing one or more cellular differentiation factors, and one or more growth factors. Such methods and compositions promote the formation of an ectopic nodule or site that can improve transplanted cell engraftment and selectively drive the development of lymphocytes and the reconstitution of the adaptive immunity after hematopoietic stem cell transplant.

Recapitulating the hematopoietic niche to reconstitute immunity

Disclosed herein are methods for generating universal MHC/HLA-compatible hematopoietic progenitor cells and methods for generating custom patient-specific MHC/HLA-compatible hematopoietic progenitor cells. Compositions comprising the universal and custom hematopoietic progenitor cells and therapeutic applications thereof are also disclosed.

Methods for generating universal and custom MHC/HLA-compatible hematopoietic progenitor cells

The present invention relates to methods and compositions for mobilizing hematopoietic stem cells and/or progenitor cells, and related methods of conditioning for engraftment of transplanted hematopoietic stem cells and/or progenitor cells, and methods of treating diseases requiring hematopoietic stem cell and/or progenitor cell transplantation.

Methods and compositions for mobilizing stem cells

The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2'-fluoro-[1,1&#x2032;-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid).

Compounds and methods useful for treating or preventing hematological cancers

Disclosed herein are methods for enhancing hematopoietic reconstitution of a subject. One method involves administering a therapeutically effective amount of an inhibitor of Embigin to a recipient subject and can also optionally include administering hematopoietic stem/progenitor cells to the subject. Another method involves administering an inhibitor of Embigin to a donor prior to harvest of hematopoietic stem/progenitor cells. Pharmaceutical compositions relating to the methods are also described.

Embigin inhibition for promotion of hematopoietic stem and progenitor cell expansion

Disclosed herein are methods for enhancing hematopoietic reconstitution of a subject. One method involves administering a therapeutically effective amount of an inhibitor of IL-18 to a recipient subject and also administering hematopoietic stem/progenitor cells to the subject. Another method involves administering an inhibitor of IL-18 to a donor prior to harvest of hematopoietic stem/progenitor cells. Pharmaceutical compositions relating to the methods are also described.

IL-18 inhibition for promotion of early hematopoietic progenitor expansion

The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.

MiR-150 for the treatment of blood disorders

The invention relates to methods for manipulating hematopoietic stem or progenitor cells, mesenchymal stem cells, epithelial stem cells, neural stem cells and related products through activation of the PTH/PTHrP receptor in neighboring cells.

Parathyroid hormone receptor activation and stem and progenitor cell expansion

Described herein are methods and compositions for expanding hematopoietic stem and progenitor cells (HSPC) ex vivo and in vivo, and methods and compositions for transplanting HSPCs and treatment of anemia in a human subject. HSPCs are expanded in the presence of an inhibitor of serine threonine kinase 38 (STK38), wherein said inhibitor is preferably an RNAi agent.

Methods for expansion of hematopoietic stem and progenitor cells

miR-150 for the treatment of blood disorders

Growing community of inventors

Weston, MA, United States of America

David T Scadden